

Supplemental Table 1. Baseline characteristics in APR+ vs APR- for ZOL group and for placebo group<sup>a</sup>

Characteristic	ZOL			Placebo		
	APR+ (n = 1639)	APR- (n = 2223)	<i>p</i> value	APR+ (n = 456)	APR- (n = 3396)	<i>p</i> value
Age (years)	72.2 ± 4.9	73.7 ± 5.5	<0.0001	73.0 ± 5.5	73.0 ± 5.4	0.98
BMI (kg/m <sup>2</sup> )	24.9 ± 4.1	25.3 ± 4.5	0.003	25.2 ± 4.4	25.4 ± 4.3	0.30
Weight (kg)	59.6 ± 10.8	60.1 ± 11.3	0.13	59.8 ± 11.9	60.7 ± 11.2	0.11
Asian race	342 (20.9)	207 (9.3)	<0.0001	118 (25.9)	420 (12.4)	<0.0001
Femoral neck BMD T-score	-2.7 ± 0.5	-2.8 ± 0.5	0.002	-2.7 ± 0.6	-2.7 ± 0.5	0.88
Prevalent vertebral fracture						
None	676 (41.2)	776 (34.9)	0.0002	162 (35.5)	1219 (35.9)	0.94
1 fracture	451 (27.5)	640 (28.8)		125 (27.4)	947 (27.9)	
2+ fractures	512 (31.2)	805 (36.2)		169 (37.1)	1229 (36.2)	
Creatinine clearance (mL/min)	64.3 ± 17.0	62.7 ± 17.5	0.005	62.8 ± 18.0	64.0 ± 17.6	0.16
<60 ml/min	709 (43.3)	1071 (48.2)	0.002	213 (46.7)	1510 (44.5)	0.37
Alkaline phosphatase (IU/L)	75.7 ± 22.3	78.3 ± 25.7	0.0005	77.2 ± 24.2	76.9 ± 24.7	0.69
Active back pain	328 (20.0)	381 (17.1)	0.03	115 (25.2)	630 (18.5)	0.0007
Diabetes	103 (6.3)	158 (7.1)	0.31	27 (5.9)	192 (5.6)	0.82
Prior bisphosphonate use	182 (11.1)	381 (17.2)	<0.0001	78 (17.2)	478 (14.1)	0.08
Current NSAID use	972 (59.3)	1240 (55.8)	0.03	274 (60.1)	1898 (55.9)	0.09
Prior calcitonin use	164 (10.0)	279 (12.6)	0.01	44 (9.7)	381 (11.3)	0.31
Current smoker	126 (7.7)	217 (9.8)	0.02	25 (5.5)	289 (8.5)	0.03

APR = acute-phase reaction; BMD = bone mineral density; BMI = body mass index; NSAID = non-steroidal anti-inflammatory drug;  
SD = standard deviation; ZOL = zoledronic acid.

<sup>a</sup> Mean  $\pm$  SD, or *n* (%)